Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10260)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
STING1
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | |||
Responsed Drug | Zalcitabine | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model |
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
Capan-2 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0026 | ||
In Vivo Model |
NOD SCID mice (394) were purchased from Charles River Laboratories. Indicated wild-type or gene knockdown PANC1 cells (5 x 106 cells) were subcutaneously injected into the dorsal side of NOD SCID mice. At day 7, these mice were administrated with the indicated drug (zalcitabine [50 mg/kg, per day by i.p.], H-151 [750 nM per mouse, once every other day by i.p.], chloroquine [50 mg/kg, once every other day by i.p.], or liproxstatin-1 [10 mg/kg, once every other day by i.p.]) for 2 weeks.
Click to Show/Hide
|
||||
Response regulation | The antiviral drug zalcitabine can suppress pancreatic cancer cell growth through the induction of autophagy-dependent ferroptotic deathin vitroandin vivo. Mechanistically, these effects are dependent on mtDNA stress-induced activation of the CGAS-STING1 pathway. | ||||
Pancreatic cancer [ICD-11: 2C10]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Stimulator of interferon genes protein (STING1) | Protein coding | |||
Responsed Drug | Zalcitabine | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model |
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
Capan-2 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0026 | ||
In Vivo Model |
NOD SCID mice (394) were purchased from Charles River Laboratories. Indicated wild-type or gene knockdown PANC1 cells (5 x 106 cells) were subcutaneously injected into the dorsal side of NOD SCID mice. At day 7, these mice were administrated with the indicated drug (zalcitabine [50 mg/kg, per day by i.p.], H-151 [750 nM per mouse, once every other day by i.p.], chloroquine [50 mg/kg, once every other day by i.p.], or liproxstatin-1 [10 mg/kg, once every other day by i.p.]) for 2 weeks.
Click to Show/Hide
|
||||
Response regulation | The antiviral drug zalcitabine can suppress pancreatic cancer cell growth through the induction of autophagy-dependent ferroptotic deathin vitroandin vivo. Mechanistically, these effects are dependent on mtDNA stress-induced activation of the CGAS-STING1 pathway. | ||||
Zalcitabine
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Inducer | ||||
Response Target | Unspecific Target | ||||
Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Autophagy | hsa04140 | ||||
Cytosolic DNA-sensing pathway | hsa04623 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model |
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
Capan-2 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0026 | ||
In Vivo Model |
NOD SCID mice (394) were purchased from Charles River Laboratories. Indicated wild-type or gene knockdown PANC1 cells (5 x 106 cells) were subcutaneously injected into the dorsal side of NOD SCID mice. At day 7, these mice were administrated with the indicated drug (zalcitabine [50 mg/kg, per day by i.p.], H-151 [750 nM per mouse, once every other day by i.p.], chloroquine [50 mg/kg, once every other day by i.p.], or liproxstatin-1 [10 mg/kg, once every other day by i.p.]) for 2 weeks.
Click to Show/Hide
|
||||
Response regulation | The antiviral drug zalcitabine can suppress pancreatic cancer cell growth through the induction of autophagy-dependent ferroptotic deathin vitroandin vivo. Mechanistically, these effects are dependent on mtDNA stress-induced activation of the CGAS-STING1 pathway. | ||||